Moclobemide compared with second-generation antidepressants in elderly people.

Area of Science:

• Geriatric Psychiatry
• Pharmacology

Background:

• Elderly patients with major depressive episodes require effective and safe treatment options.
• Second-generation antidepressants have varying efficacy and side effect profiles in older adults.

Purpose of the Study:

• To compare the efficacy and safety of moclobemide with mianserin and maprotiline in elderly patients with major depressive episodes.
• To evaluate moclobemide as a potential first-line therapy for geriatric depression.

Main Methods:

• Two multicenter studies were conducted.
• Study 1: 80 elderly patients randomized to moclobemide (300-500 mg/day) or mianserin (75-125 mg/day) for 4 weeks.
• Study 2: 39 hospitalized elderly patients randomized to moclobemide (150-300 mg/day) or maprotiline (75-150 mg/day) for 6 weeks. Hamilton Rating Scale for Depression (HRSD) was used for assessment.

Main Results:

• Both studies showed significant reductions in HRSD scores in all treatment groups.
• Moclobemide demonstrated comparable efficacy to mianserin and maprotiline, with no significant differences in overall assessment of efficacy or tolerance.
• Efficacy was rated good/very good for 60% (Study 1) and over 90% (Study 2) of patients, with tolerance rated good/very good for 85% (Study 1) and 80-75% (Study 2).

Conclusions:

• Moclobemide is as effective and well-tolerated as mianserin and maprotiline in elderly patients with major depressive episodes.
• The favorable safety profile of moclobemide supports its consideration as a first-line treatment for depression in the elderly population.